RAPPLER
WASHINGTON, USA – An arthritis drug that was being closely watched for its potential use against COVID-19 has delivered disappointing results in clinical trials, its makers said Monday, April 27.
Kevzara, which is made by Regeneron and Sanofi, does not attack the novel coronavirus but instead inhibits an abnormal immune ...
Post a Comment